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ABSTRACT Epithelial cell differentiation and polarized migration associated with epithelial-
to-mesenchymal transition (EMT) in cancer requires integration of gene expression with 
cytoskeletal dynamics. Here we show that the PDZ-LIM domain protein PDLIM2 (Mystique/
SLIM), a known cytoskeletal protein and promoter of nuclear nuclear factor κB (NFκB) and 
signal transducer and activator of transcription (STAT) degradation, regulates transcription 
factor activity and gene expression through the COP9 signalosome (CSN). Although re-
pressed in certain cancers, PDLIM2 is highly expressed in invasive cancer cells. Here we show 
that PDLIM2 suppression causes loss of directional migration, inability to polarize the cytoskel-
eton, and reversal of the EMT phenotype. This is accompanied by altered activity of several 
transcription factor families, including β-catenin, Ap-1, NFκB, interferon regulatory factors, 
STATs, JUN, and p53. We also show that PDLIM2 associates with CSN5, and cells with sup-
pressed PDLIM2 exhibit reduced nuclear accumulation and deneddylation activity of the CSN 
toward the cullin 1 and cullin 3 subunits of cullin-RING ubiquitin ligases. Thus PDLIM2 inte-
grates cytoskeleton signaling with gene expression in epithelial differentiation by controlling 
the stability of key transcription factors and CSN activity.
INTRODUCTION
Epithelial-to-mesenchymal transition (EMT) involves a complex se-
ries of molecular and cellular events by which epithelial cells ac-
quire a migratory and invasive phenotype during embryonic de-
velopment and in cancer progression (reviewed in Thiery et al., 
2009; Nieto and Cano, 2012). EMT is associated with suppression 
of epithelial genes such as E-cadherin, loss of cell polarity, and 
loss of cell–cell contacts enabling cell migration and invasion. In 
turn, reverse differentiation facilitates colonization and secondary 
growth at new sites and requires reexpression of E-cadherin, a 
process referred to as mesenchymal-to-epithelial reverting transi-
tion (MErT; Chao et al., 2010; Tsai et al., 2012). Although much evi-
dence exists for reversible epithelial differentiation in metastasis, 
the mechanism of its regulation at the cellular level is not well 
understood.
The PDZ-LIM domain protein PDLIM2 (also known as Mystique 
or SLIM) is a cytoskeletal and nuclear protein that was identified in 
cornea epithelial cells (Torrado et al., 2004), in fibroblasts trans-
formed by overexpression of the Insulin-like Growth Factor 1 (IGF-1) 
Receptor (Mystique), and in epithelial cancer cells, where it is re-
quired for cell adhesion and migration (Loughran et al., 2005a,b). In 
T-lymphocytes, PDLIM2 (SLIM) regulates the stability of signal trans-
ducer and activator of transcription (STAT) and nuclear factor κB 
(NFκB)-p65 transcription factors in the nucleus (Tanaka et al., 2005, 
2007, 2011; Guo et al., 2010), and in macrophages, differentiation 
causes increased PDLIM2 expression and sequestration in the cyto-
plasm (Healy and O’Connor, 2009).
Several studies implicate PDLIM2 expression with tumorigenesis 
and potentially with tumor suppression. PDLIM2 is located on chro-
mosome 8p21 (Loughran et al., 2005a), a region that is disrupted in 
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PDZ- and LIM-domain proteins have im-
portant functions in controlling cell fate 
(Zheng et al., 2010). We hypothesized that 
PDLIM2 expression is associated with the 
differentiation status of epithelial cancer 
cells during transformation or reversible 
EMT. We tested this by stably suppressing 
PDLIM2 expression in DU145 and MDA-
MB-231 cells that express high levels of en-
dogenous PDLIM2. Our findings demon-
strate that PDLIM2 controls the stability and 
activity of key transcription factors and activ-
ity of the COP9 signalosome (CSN) in re-
versible epithelial cell differentiation.
RESULTS
PDLIM2 suppression increases 
proliferation but decreases clonogenic 
growth
Previously we showed that PDLIM2 expres-
sion is higher in androgen-independent, mi-
gratory prostate carcinoma cell lines DU145 
and PC-3 than in androgen-dependent 
PPC1 and Alva31 cell lines (Loughran et al., 
2005b). PDLIM2 is located at the cytoskele-
ton, at points of focal adhesions, and in the 
nuclei of DU145 cells (Figure 1A). Moreover, 
it is present in the soluble nuclear fraction 
but not in the insoluble nuclear fraction 
(Figure 1B), in agreement with observations 
in T-lymphocytes (Tanaka et al., 2007). To in-
vestigate whether PDLIM2 is required for 
the migratory or EMT phenotype, we used 
short hairpin RNA (shRNA)–encoding vec-
tors to stably suppress PDLIM2 in DU145 
cells. Three clones of control (shScramble) 
cells or cells with PDLIM2 suppressed by at 
least 60% (shPDLIM2) were isolated (Figure 
1C), and two clones of each were used for 
subsequent experiments. ShPDLIM2 DU145 
cells displayed a noticeably altered mor-
phology compared with shScramble cells, 
with increased cell–cell contact and less-
pronounced fibroblastoid morphology, in-
cluding decreased ability to scatter (Figure 
1D). ShPDLIM2 DU145 cells also exhibited significantly increased 
proliferation rates compared with control cells (Figure 1E). PDLIM2 
can suppress anchorage-independent growth (Loughran et al., 
2005a; Qu et al., 2010a,b), but we found that shPDLIM2 DU145 cells 
formed significantly fewer colonies in soft agarose than shScramble 
cells (Figure 1F). We conclude that suppression of PDLIM2 in DU145 
cells increases cell–cell contact and anchorage-dependent cell pro-
liferation but decreases anchorage-independent cell proliferation.
Suppression of PDLIM2 decreases polarized cell migration
We next investigated the migratory capacity of shPDLIM2 DU145 
cells using wound-healing and electrical cell-substrate impedance 
sensing (ECIS) assays, which allow real-time quantification of cell 
migration rates. Cells were grown to confluency on collagen-coated 
electrodes that monitor the capacitance of the culture (typically 
0–2 nF), which increases sharply to approximately 6 nF when an elec-
tric current is applied to generate the wound (Figure 2A). Migration 
many cancers (Macartney-Coxson et al., 2008). In colon cancer, 
PDLIM2 expression is slightly decreased in tumor compared with 
normal colon tissue, and although a single nucleotide polymor-
phism was detected in metastasis, no significant difference in ex-
pression was observed between tumor and liver metastasis 
(Macartney-Coxson et al., 2008). The PDLIM2 gene is methylated in 
lung cancer (Pfeifer and Rauch, 2009) and in several cell lines (Qu 
et al., 2010a,b). PDLIM2 promotes degradation of the human T-cell 
virus type 1 (HTLV-1) Tax oncoprotein and is repressed in response 
to HTLV1-mediated transformation of T lymphocytes (Yan et al., 
2009; Zhao et al., 2009; Fu et al., 2010). Overexpression of PDLIM2 
in cancer cell lines decreases anchorage-independent growth and 
reduces tumor growth in vivo, again suggesting a tumor-suppressive 
function (Loughran et al., 2005a; Qu et al., 2010a,b). However, 
PDLIM2 is highly expressed in cell lines derived from metastatic can-
cer, including androgen-independent prostate cancer cell lines 
(Loughran et al., 2005b).
FIGURE 1: PDLIM2 suppression alters morphology, proliferation, and clonogenic growth. 
(A) DU145 cells were immunostained for PDLIM2 (gray/green), counterstained with Hoechst 
(blue; N), and photographed. Scale bar, 10 μm. Arrows indicate points of focal adhesion. 
(B) Subcellular fractionations of cytoplasmic (CY), soluble nuclear (SN), and insoluble nuclear (IN) 
fractions of DU145 cells analyzed by Western blotting for PDLIM2 expression. Purity of the 
fractions was confirmed using markers of each fraction: CY (HSP90), SN (PARP), and IN (lamin B). 
(C) Clones of DU145 cells stably expressing scrambled shRNA (shScramble) or PDLIM2 shRNA 
(shPDLIM2) were analyzed by Western blotting. PDLIM2 expression normalized to tubulin 
loading control, relative to shScramble clone2, quantified by densitometry using Odyssey 
software. (D) Cells were plated at low densities on collagen for 5 d, and colonies were 
photographed with phase microscopy. Representative micrographs of three separate 
experiments. Scale bar, 50 μm. (E) Cell cultures seeded at equal densities were monitored by 
crystal violet staining over 5 d. Data represent an average of six wells from a representative 
experiment. (F) Cells seeded at equal densities in soft agarose were cultured for 4 wk, when 
colonies were stained with crystal violet and counted. Data represent mean colonies per well 
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approximately 8 h postwounding, and they reach 1–3 nF by 25 h, 
indicating that these cells “sense” the wound and move direction-
ally to fill it. However, after an initial slight decrease of approximately 
1 nF at 8 h, shPDLIM2 DU145 cells show little change in capacitance 
up to 25 h postwounding, never reaching capacitance levels <4 nF. 
This indicates that suppression of PDLIM2 greatly inhibits directional 
cell migration in DU145 cells. In addition, time-lapse movies of 
wound-healing assays confirm that in contrast to controls, shPDLIM2 
cells do not migrate directionally to fill the wound (Supplemental 
Movies S1 and S2).
To establish whether the disruption in directional migration of 
shPDLIM2 DU145 cells was associated with an inability to polarize 
the actin cytoskeleton, we analyzed the orientation of microtubule-
organizing centers (MTOCs), whose orientation toward the front of 
the cell is critical for migrating cells to “sense” the wound and move 
directionally (Cuschieri et al., 2007). Immunofluorescence imaging 
of γ-tubulin within centrosomes of wounded DU145 cell monolayers 
(Cuschieri et al., 2007) demonstrated that in shScramble cells, the 
centrosomes were located predominantly at the anterior edge of 
the cell nucleus, toward the leading edge of migrating cells (Figure 
2B). In contrast, centrosomes in shPDLIM2 DU145 cells were located 
behind the nucleus, away from the direction of migration (Figure 
2B). The numbers of cells with centrosomes at the front, middle, or 
behind the nucleus indicated significant reduction in directional 
MTOC localization in shPDLIM2 cells (Figure 2B). Thus suppression 
of PDLIM2 results in reduced ability of cells to polarize and migrate 
directionally in response to wounding. This conclusion is supported 
by sustained phosphorylation of the actin-depolymerizing protein 
cofilin in shPDLIM2 cells at 6 h postwounding, whereas decreased 
phospho-cofilin in wounded shScramble cells indicates turnover of 
actin filaments necessary for directed migration (Figure 2C).
Thus PDLIM2 is required to maintain the mesenchymal pheno-
type and allow cells to polarize and migrate directionally.
PDLIM2 suppression reverses EMT and suppresses β-catenin 
activity
To test whether PDLIM2 suppression reverses EMT, we investigated 
the status of the epithelial marker E-cadherin and the transcriptional 
regulators of EMT, Snail and β-catenin (Schmalhofer et al., 2009). 
E-cadherin protein and mRNA levels were significantly increased in 
shPDLIM2 DU145 cells (Figure 3, A and B), and this was accompa-
nied by decreased protein expression of the mesenchymal marker, 
vimentin (Supplemental Figure S1, A and B). Of interest, Snail pro-
tein expression was markedly decreased, and overexpression of 
PDLIM2 in other cell types caused reexpression of Snail protein 
without any changes in mRNA expression (Supplemental Figure S1, 
C and D). β-Catenin protein levels were increased in shPDLIM2 
DU145 cells, although mRNA levels were unaltered (Figure 3, A-C; 
Supplemental Figure S1B). Increased β-catenin was prominently 
located at cell–cell junctions in association with E-cadherin, and 
there was a concomitant decrease in nuclear β-catenin levels 
(Supplemental Figure S1, E and F). Reduced nuclear expression of 
β-catenin correlated with decreased transcriptional activity indicated 
by reduced mRNA expression of its target genes, c-Myc, c-Jun, and 
Cyclin D1, compared to controls (Supplemental Figure S1G).
We also tested whether the increased cell junction expression of 
β-catenin was due to protein stabilization. After exposure to the pro-
teasome inhibitor MG132 for up to 24 h, control cells displayed a 
marked increase in β-catenin levels, indicating that β-catenin is nor-
mally degraded in these cells. In contrast, shPDLIM2 DU145 cells 
displayed high basal levels of β-catenin (time 0) and no further 
accumulation in the presence of MG132, indicating resistance to 
of cells to fill the wound is represented by a progressive decrease in 
capacitance over time. As can be seen in Figure 2A, shScramble 
cells display a time-dependent decrease in capacitance starting at 
FIGURE 2: Suppression of PDLIM2 decreases polarized, directional cell 
migration. (A) Two clones each of shScramble and shPDLIM2 DU145 
cells were electrically wounded by applying a voltage using the ECIS 
system (dark arrow). Capacitance of cells migrating on the electrode 
was measured over 25 h as described in Materials and Methods. (B) 
Confluent shScramble and shPDLIM2 DU145 cells were wounded with 
a pipette tip, and cells were allowed to migrate for 6 h. Cells were 
fixed and immunostained for γ-Tubulin to label MTOC (centrosomes; 
green, small arrows). Nuclei were counterstained with Hoechst (blue). 
Large arrows indicate the direction of migration. Scale bars, 50 μm 
(top), 20 μm (bottom). Centrosomes were scored according to position 
relative to the nucleus (front, middle, and back), as described in 
Materials and Methods (**p < 0.005, ***p < 0.0005). (C) Confluent 
monolayers of two clones of each cell type were scored with several 
wounds using a multichannel pipette. At 6 h postwounding, cells were 
lysed and probed for phospho-cofilin serine 3 expression by Western 
blotting. Results represent one of three independent experiments with 
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cell–cell contact (Figure 3E) and increased 
E-cadherin mRNA and protein expression 
(Figure 3, F and G), whereas Snail expres-
sion was markedly reduced compared with 
controls (Figure 3H). ShPDLIM2 MDA-
MB-231 cells also exhibited increased prolif-
eration and decreased anchorage-indepen-
dent growth (Supplemental Figure S2). A 
role for EMT in breast cancer is supported 
by data from public databases (http://
glados.ucd.ie/BreastMark/index.html), indi-
cating that PDLIM2 expression is associated 
with poor outcome in basal breast cancers.
Altered NFκB target gene expression 
in cells with suppressed PDLIM2
Overexpressed PDLIM2 can target the p65 
subunit of NFκB for degradation, thus sup-
pressing its transcriptional activity (Tanaka 
et al., 2007; Qu et al., 2010a,b). NFκB activ-
ity is associated with tumorigenesis and 
EMT in different cancer types (Maier et al., 
2010). Therefore we investigated whether 
NFκB activity was altered in DU145 cells 
with suppressed PDLIM2.
First, we observed a slight but significant 
increase in total level of p65 protein in shP-
DLIM2 DU145 compared with control cells 
(+1.24-fold; Figure 4A). We next assessed 
the mRNA expression of selected NFκB tar-
get genes (Figure 4B). PLAU, CXCL10, and 
interleukin 8 (IL-8) mRNA levels were sup-
pressed, whereas ID1 and vascular endothe-
lial growth factor C (VEGF-C) mRNA levels 
were increased in shPDLIM2 DU145 cells. 
This indicates that suppression of PDLIM2 
differentially regulates NFκB target genes. 
Of interest, we found that there was no sig-
nificant difference in basal NFκB promoter 
activity in shScramble and shPDLIM2 cells 
(Figure 4C). However, when p65 was coex-
pressed with the NFκB reporter, there was a 
moderate but significant increase in tumor 
necrosis factor-α (TNF-α)–mediated NFκB 
promoter activity in shPDLIM2 cells (Figure 
4D). Taken together, these data indicate that 
although PDLIM2 suppression alters expres-
sion of several NFκB target genes, the effect 
on basal NFκB activity in DU145 cells is 
minimal.
PDLIM2 regulates a broad 
transcriptional program and 
transcription factors
Our data suggest that the effect of PDLIM2 
suppression on EMT is not entirely medi-
ated by NFκB. To gain insight into the mechanisms by which PDLIM2 
acts, we next determined the overall gene expression profile of 
DU145 cells with suppressed PDLIM2. We identified 457 genes that 
had altered expression in shPDLIM2 compared with shScramble 
cells. These included 213 down-regulated genes and 244 up-regu-
lated genes (fold change, ≥1.5; p ≤ 0.05; Supplemental Table S1). 
proteasomal degradation (Figure 3D). Thus PDLIM2 suppression 
reduces β-catenin activity and reverses EMT.
To test whether PDLIM2 suppression reverses EMT in other 
cells, we stably expressed PDLIM2 shRNA in MDA-MB-231 breast 
cells and observed a similar reversal of the EMT phenotype. 
MDA-MB-231 cells with suppressed PDLIM2 exhibited increased 
FIGURE 3: Reversal of EMT with increased E cadherin and reduced β-catenin activity. (A) Cell 
lysates of shScramble and shPDLIM2 DU145 cells were probed for expression of E-cadherin, 
β-catenin, and PDLIM2, with tubulin as loading control. (B) Total RNA was extracted from 
shScramble and shPDLIM2 DU145 cells, and quantitative PCR was performed for E-cadherin, 
β-catenin, and PDLIM2 expression. β-2-Microglobulin (β2M) was used as control. Gene 
expression levels are normalized to shScramble samples and expressed as fold change. 
(C) Subcellular cytoplasmic (CY) and nuclear (N) fractions of shScramble and shPDLIM2 DU145 
cells were analyzed by Western blotting for Snail expression. Purity of the fractions was 
confirmed by probing for markers of each fraction: CY (tubulin) and N (PARP). (D) Western blot 
analysis of β-catenin and tubulin expression in shScramble and shPDLIM2 DU145 cells treated 
with MG132 (10 μM). (E) Clones of MDA-MB-231 cells transfected with shScramble or shPDLIM2 
photographed under phase contrast microscopy. Scale bar, 100 μm. (F) Western blotting of 
E-cadherin and PDLIM2 in shScramble and shPDLIM2 MDA-MB-231 cells. Loading control is 
actin. (G) Quantitative PCR for E-cadherin and PDLIM2 on total RNA extracted from shScramble 
and shPDLIM2 MDA-MB-231 cells. β2M was used as the control, and gene expression levels 
normalized to shScramble samples are expressed as fold change. (H) Lysates of shScramble and 
shPDLIM2 MDA-MB-231 cells were probed for expression of β-catenin, Snail, PDLIM2, and 
tubulin as loading control. Results represent one of three similar independent experiments. 
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tumor,” “invasion of cells,” and “invasion of 
tumor cell lines.” Again, other decreased 
functions predicted by IPA are consistent 
with the role of PDLIM2 function in he-
matopoietic cells, such as “mobilization of 
hematopoietic progenitor cells” and “attrac-
tion of neutrophils and phagocytes” (Sup-
plemental Table S3). Of interest, the pre-
dicted activation state of several transcription 
factor families was altered, including TRIM24, 
Gli1, Ap-1, NFκB, and interferon regulatory 
factors (Figure 6B and Supplemental Table 
S4). Moreover, IPA predicted a mechanistic 
network in which NFκB, STATs, and JUN 
transcriptional activity is inhibited, which is 
consistent with the roles of these transcrip-
tion factors in transformation and metastasis 
(Supplemental Figure S3). This network also 
predicts the inhibition of β-catenin activity 
(CTNNB1), even though its mRNA levels are 
unchanged, which is in agreement with data 
shown in Figure 3 and Supplemental Figure 
S1. On the other hand, acetyltransferase 
EP300, p53, and the glucocorticoid receptor 
NR3C1 are predicted to be activated (Sup-
plemental Table S4 and Figure 6B). Overall 
these predicted events correlate well with 
the observed effects on the EMT phenotype 
when PDLIM2 is suppressed.
We next validated expression of selected 
genes associated with the top biofunctions 
based on their known involvement in EMT/
MErT or their frequent appearance in the 
biofunction groups. As shown in Figure 6, C 
and D, the expression of WWOX1, CITED2, 
FPN1, GNG2, and MYL9 mRNA was greatly 
increased in shPDLIM2 DU145 cells, whereas 
IGFBP3 expression was decreased. Thus 
these data and also the mRNA levels of sev-
eral NFκB target genes shown in Figure 4B 
are consistent with the expression profiles determined by microar-
ray analysis.
Overall the results indicate that PDLIM2 suppression alters 
the expression of a large number of genes and the activity of 
key transcriptional regulators of epithelial cell differentiation and 
malignancy.
PDLIM2 regulates CSN5 nuclear translocation and activity
On the basis of our observation that PDLIM2 suppression alters key 
transcriptional regulators of epithelial cell differentiation and on its 
previously described function in promoting degradation of NFκB 
and STATs (Tanaka et al., 2005; Guo et al., 2010), we hypothesized 
that PDLIM2 regulates the cellular protein degradation machinery at 
a level that impinges on multiple transcriptional regulators. To 
address this, we searched for PDLIM2-interacting proteins and iden-
tified subunits of the CSN complex, which controls protein stability 
and activity of several transcription factors associated with EMT 
(reviewed in Lee et al., 2011). The CSN consists of eight subunits 
(CSN1–8), several of which form smaller complexes and may also 
function as monomers (Kato and Yoneda-Kato, 2009). PDLIM2 could 
be coimmunoprecipitated with CSN5 (Jab1), the catalytic subunit 
of the CSN (Shackleford and Claret, 2010), in DU145 cell lysates 
Figure 5 shows a basic heat map of the top 100 differentially ex-
pressed genes (50 most up-regulated and 50 most down-regulated) 
based on fold changes.
The functional significance of the gene expression profile was 
objectively assessed used Ingenuity Pathway Analysis (IPA), which 
associates known signaling pathways and networks with the differ-
entially expressed genes (Supplemental Table S2). This analysis re-
vealed that the most affected biofunction in shPDLIM2 cells was 
“cancer” (Figure 6A), followed by “reproductive system disease,” 
both of which are consistent with reversion of EMT in a prostate 
cancer cell line. Other altered biofunctions consistent with the phe-
notype of shPDLIM2 cells are “cellular movement,” “cellular growth 
and proliferation,” and “cell morphology.” The IPA software also 
predicted that PDLIM2 suppression would alter “cellular develop-
ment,” “hematological system development and function,” and 
“hematopoiesis” (Figure 6A). These may reflect PDLIM2 function in 
lymphocytes and macrophages (Tanaka et al., 2007, 2011; Healy 
and O’Connor, 2009; Qu et al., 2012).
Using IPA, we could also predict the “activation state” of specific 
cellular functions included within each biofunction (Figure 6A). This 
analysis, shown in Supplemental Table S3, indicates several functions 
consistent with the phenotype we observed, including “genital 
FIGURE 4: Suppression of PDLIM2 does not alter basal NFκB activity in DU145 cells. (A) Western 
blotting for NFκB p65 expression in shScramble and shPDLIM2 DU145 cells. Densitometry 
measurements of the average fold difference in p65 expression in shPDLIM2 cells compared with 
shScramble controls from six independent experiments. (B) Quantitative PCR on total RNA 
extracted from shScramble and shPDLIM2 cells for PLAU, CXCL10, IL8, ID1, VEGF-C, and PDLIM2 
mRNA expression. β2M mRNA levels were used as a control; expression levels were compared to 
shScramble mRNA levels and expressed as fold change. (C) shScramble or shPDLIM2 DU145 cells 
were transfected with a dual-luciferase plasmid containing an NFκB promoter and cotransfected 
with pCMV-empty vector (pCMV-EV) or pCMV-p65 construct. (D) Cells were transfected as in C 
and treated with 20 ng/ml TNF-α for 4 h before analysis. Luciferase activity in p65-transfected 
cells normalized to that of Renilla luciferase is presented as mean fold change of activity in 
shScramble cells expressing the empty vector ± SEM in triplicate samples and three independent 
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shPDLIM2 cells. Peptide spots that showed less reactivity with the 
anti-PDLIM2 antibody on shPDLIM2 lysates were considered posi-
tive. From this we observed PDLIM2 binding to the CSN5 and CSN8 
peptides, slightly to CSN3, but not to CSN1, 2, 4, 6, or 7 (Figure 7 
and Supplemental Table S5). To identify more specific sites of 
interaction, we further analyzed positively reacting peptides from 
CSN5 and CSN8 using amino acid substitution arrays (alanine for all 
amino acids and glutamic acid for alanine; Supplemental Table S5). 
From this analysis we identified one peptide for CSN5 (166-VIDP-
TRTISAGKVNLGAF-183) for which binding was greatly disrupted by 
substitution of Lys-180. For CSN8, binding to one peptide (-ADST-
TRMVLPRKPVAGAL-) was disrupted by substitution of Arg-160 and 
165, Lys-166, and Ala-169 and 171. These amino acids are found in 
three peptides from the ones interacting, with increased fold of 3.9, 
2.4, and 7.3, respectively (Figure 7 and Supplemental Table S5). The 
other peptides tested did not lose binding with substitution of a 
single amino acid, suggesting that they are not essential but may be 
involved as indirect binding sites. These results confirm that PDLIM2 
binds to CSN5 and CSN8.
Coimmunoprecipitation of PDLIM2 with CSN5 and enhanced 
nuclear location of CSN5 could also be observed when PDLIM2 was 
overexpressed in MCF-7 cells. Taken together, these data indicating 
that the PDLIM2-CSN5 interaction is functional in other cells (Sup-
plemental Figure S4).
The CSN deconjugates Nedd8 (deneddylation) from the cullin 
family of proteins, thereby regulating protein degradation com-
plexes, including the Skp1-cullin-F box (SCF) complex (Kato and 
Yoneda-Kato, 2009). When cullin1 (Cul1) is deneddylated the target 
substrate levels may be stabilized. Therefore, to test whether CSN 
activity is regulated by PDLIM2, we compared Cul1 neddylation in 
shScramble and shPDLIM2 DU145 cells. As can be seen in Figure 
8A, more neddylated Cul1 accumulates in the nucleus with shP-
DLIM2 than in controls. This is accompanied by greatly increased 
stability of the cell cycle regulator p27, a key target of CSN5 activity 
(Shackleford and Claret, 2010; Figure 8B). Similarly, nuclear cullin3 
neddylation was increased in shPDLIM2-DU145, and p27 was in-
creased in the cytoplasm of these cells (Figure 8C). The effect of 
PDLIM2 on CSN5-mediated regulation of p27 is further supported 
by the observation that in cells in which PDLIM2 is overexpressed, 
P27 protein levels are decreased (Figure 8D). Taken together, these 
data indicate that PDLIM2 associates with CSN5 and enhances its 
nuclear localization and activity. Reduced CSN activity is also consis-
tent with the effects of PDLIM2 suppression on enhanced β-catenin 
stability (Figure 3D) and with the altered activity of several transcrip-
tional regulators whose stability and activity is regulated by the cul-
lin-RING ubiquitin ligases (p53, Smad4, NFκB, JUN, AP-1; Figure 
6B; Kato and Yoneda-Kato, 2009; Shackleford and Claret, 2010).
DISCUSSION
The findings of this study, combined with the documented functions 
in T-lymphocytes and macrophage differentiation, demonstrate that 
PDLIM2 is a key regulator of cellular differentiation. We show that 
suppression of PDLIM2 is sufficient to suppress a gene expression 
program necessary for maintaining a mesenchymal phenotype in 
cancer cells and activate an epithelial gene expression program. Of 
importance, we show that PDLIM2 regulates the activity of several 
key transcription factor families, as well as the nuclear localization 
and activity of the CSN subunit CSN5.
PDLIM2 has one PDZ domain that associates with the actin cy-
toskeleton via α-actinin (Loughran et al., 2005a) and one LIM do-
main that has potential to associate with different protein partners 
(Krcmery et al., 2010). PDLIM2 shuttles between the cytoskeleton 
(Figure 7A), MCF7 cells overexpressing PDLIM2, and MDA-MB-231 
cells (Supplemental Figure S4). Nuclear levels of both CSN5 and 
CSN2 were reduced in shPDLIM2 DU145 cells (Figure 7, B and C).
To test whether PDLIM2 associates with individual subunits or 
potentially the entire CSN complex, we used peptide arrays encom-
passing the entire sequence of each CSN subunit (spot synthesized 
as 18-mer peptides overlapping by five amino acids). Each array 
was overlaid with cell lysate from DU145 shScramble or DU145 
FIGURE 5: Suppression of PDLIM2 alters global gene expression in 
DU145 cells. A basic heat map demonstrating the top 100 
differentially expressed genes (50 most up-regulated and 50 most 
down-regulated), based on fold changes generated using JColorGrid 
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FIGURE 6: PDLIM2 suppression alters activity of key transcription factor families. (A) The top 20 biofunctions from the 
IPA of genes differentially expressed in shPDLIM2-DU145, based on most-significant p values. Data are presented as 
–log(p value) for the probability that the specific function is affected. A significance threshold of p = 0.05 is represented 
by –log(p value) = –1.301 (gray dashed line). (B) Changes in the activation status of transcription factors were plotted 
based on their activation z-score from IPA. (C–E) Quantitative PCR analysis of selected genes differentially expressed in 
the microarray gene list performed in two separate shPDLIM2-DU145 clones. Gene expression was normalized to levels 
in shScramble clones, using β2M as control and expressed as mean fold change ± SEM from three independent 
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proteins, such as LASP-1 and Four and a 
Half LIM domain (FHL) 2 protein, have been 
described as courier proteins that connect 
genome activity with cytoskeleton dynamics 
(Olson and Nordheim, 2010). Of interest, 
FHL-2 enhances nuclear β-catenin transcrip-
tional activity in cardiac stem cells (Olson 
and Nordheim, 2010). Our observation of 
decreased nuclear β-catenin and increased 
stabilization at cell–cell junctions in shP-
DLIM2 cells suggests a similar role for 
PDLIM2 in enhancing β-catenin transcrip-
tional activity to promote EMT. Similarly, the 
LIM domain–only proteins (LMO1–4) are 
proposed to act as coactivators or repres-
sors in nucleating or disrupting transcrip-
tional complexes (Matthews et al., 2013). 
Indeed, overexpression of LMO2 in andro-
gen-dependent LNCAP prostate cancer 
cells is sufficient to induce EMT (Ma et al., 
2007).
PDLIM2 suppression in DU145 cells al-
tered the expression of many genes and 
transcription factors associated with the 
EMT phenotype. Genes associated with tu-
morigenesis were suppressed, and genes 
associated with tumor suppression were in-
creased. These included WWOX1, which is 
frequently suppressed in prostate and other 
cancers (Del Mare et al., 2009); CITED2, a 
key transcription factor in mouse embryonic 
cells primed to undergo MErT (Bard et al., 
2008) and whose suppression increases co-
lon cancer invasiveness (Bai and Merchant, 
2007); FPN1, which is suppressed in meta-
static breast cancer (Pinnix et al., 2010); and 
IGFBP-3, which enhances transforming 
growth factor β–promoted EMT (Natsuizaka 
et al., 2010). Genes associated with cellular 
movement were also altered by PDLIM2 
suppression. These include GNG2, which 
regulates the Rho family of small GTPases 
(Ueda et al., 2008), and MYL9, which is im-
plicated in actin cytoskeleton contractility 
(Medjkane et al., 2009). Overall the profile 
indicates that PDLIM2 has an essential func-
tion in integrating signals from the actin cy-
toskeleton with gene expression to deter-
mine cell phenotype.
Our data strongly suggest that PDLIM2 
mediates its effects on transcription factors 
by associating with the CSN and enhancing 
its activity. Cells with suppressed PDLIM2 
have reduced nuclear targeting of CSN 
subunits and reduced deneddylation of 
cullin 1, whereas overexpression of PDLIM2 
is sufficient to promote nuclear accumula-
tion of CSN5. The CSN has a complex role 
in regulating protein stability, which is de-
termined by expression levels of its subunits and the cellular sig-
naling context (Lee et al., 2011). Its actions can be mediated 
through its regulation of cullin-RING ligases, RING-containing 
and nucleus (Healy and O’Connor, 2009; Krcmery et al., 2010) and 
thus is well suited for integration of cytoskeleton signals with gene 
expression in cell polarization and migration. Other LIM-domain 
FIGURE 7: PDLIM2 interacts with CSN subunits CSN5 and CSN8 and regulates CSN5 
localization. (A) CSN5 immunoprecipitates from DU145 shScramble cells were assessed by 
Western blotting for PDLIM2 interaction. Beads and lysate without antibody (–Ab) is a negative 
control. (B) Western blotting for CSN5 and CSN2 expression in cytoplasmic (CY) and nuclear (N) 
extracts of DU145 shScramble or shPDLIM2 cells. Loading controls are tubulin (CY) and PARP (N). 
(C) Subcellular localization of CSN5 was assessed in shScramble and shPDLIM2 DU145 cells by 
immunostaining. Scale bars, 10 μM. (D) Peptide arrays were generated for all CSN subunits and 
overlaid with lysate from DU145 shScramble and DU145 shPDLIM2 cells. Spots that showed less 
reactivity with the anti-PDLIM2 antibody on PDLIM2 lysates were considered positive. CSN5 and 
CSN8 arrays showed intense spots of interaction with PDLIM2. Positive peptides were then 
synthesized with successive amino acid substitution (bottom, with graph and substitution arrays). 
Graphs represent intensity of interaction of peptides with PDLIM2 expressed as percentage of 
the intensity of the original interaction peptide. Alanines were substituted by glutamic acids; all 
other amino acids were substituted with alanines. (E, F) Immunoprecipitations (IPs) for CSN5 
(E; top), PDLIM2 (E; bottom), or CSN8 (F), were performed from lysates of MCF7 cells stably 
transfected with GFP-empty vector (EV) or GFP-PDLIM2 as described in Materials and Methods. 
Immunocomplexes were probed for each protein by Western blotting. Controls for IPs included 
no lysate (–Ly) and beads plus lysate only, no antibody (–Ab). See also Supplemental Figure S4 
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Huang et al., 2009; Kato and Yoneda-Kato, 2009; Schweitzer and 
Naumann, 2010; Lee et al., 2011). Moreover, CSN subunits may 
act as monomers, and CSN5 can positively regulate several tran-
scription factors, including NFκB, JUN/AP-1, Hif1α, and E2F1 
(reviewed in Kato and Yoneda-Kato, 2009; Shackleford and Claret, 
2010). Of note, the mechanistic network generated by IPA with the 
DU145 RNA profile indicates inhibition of CTNNB1 (β-catenin), 
NFκB, and JUN, whereas p53 activity is activated. This further sup-
ports the conclusion that reduced CSN activity mediates the ef-
fects of PDLIM2 suppression on transcription factor activity and 
gene expression. Of interest, CSN5 and CSN8 have no common 
sequence, interact not directly but through CSN4, and have op-
posite location inside the CSN complex (Kapelari et al., 2000). 
Because we did not detect interaction of PDLIM2 with CSN4, it is 
more likely that PDLIM2 is interacting directly with the CSN com-
plex and thereby regulating its deneddylation activity toward 
cullins.
Reduced CSN activity is also intriguing from the perspective of 
PDLIM2’s effects on NFκB activity. PDLIM2 promotes degradation 
of STATs and NFκB in T-lymphocytes (Tanaka et al., 2005, 2007, 
2011; Guo et al., 2010). In DU145 cells with suppressed PDLIM2, 
we noted no effect on basal NFκB activity, and a subset of NFκB 
target genes was down-regulated, whereas other target genes 
were up-regulated. Several of the down-regulated genes (PLAU, 
IL-8, and CXCL10) are known NFκB-target genes that promote can-
cer progression (reviewed in Baud and Karin, 2009). NFκB-target 
genes that were increased include VEGF-C, which is associated 
with angiogenesis (Watari et al., 2008), and ID1, which represses 
stem cell differentiation (Romero-Lanman et al., 2012). Of interest, 
IPA predicts overall inhibition of the NFκB complex activity (z score, 
−2.901, p < 0.0001) rather than activation. This indicates that 
PDLIM2 does not simply promote NFκB degradation and may in-
stead reflect the cellular context in determining PDLIM2’s effects on 
CSN activity.
PDLIM2 may now be added to a small group of LIM-domain 
proteins that regulate phenotypic changes in cancer progression 
(Craene and Berx, 2013). This has important consequences for tu-
morigenesis and cancer progression, for which PDLIM2 expres-
sion could determine the potential of cancer cells to undergo re-
versible EMT, a process necessary for tumor growth (Tsai et al., 
2012). PDLIM2 is highly expressed in certain cells with an EMT 
phenotype (this study; Loughran et al., 2005a); however, its ex-
pression is suppressed by methylation in breast and lung cancer 
cells (Pfeifer and Rauch, 2009; Qu et al., 2010a). Suppression of 
PDLIM2 by methylation would facilitate cellular transformation 
and tumor growth, whereas subsequent up-regulation in cells 
primed for invasion would facilitate the mesenchymal, migratory 
(EMT) phenotype required for metastasis. Our data demonstrate 
that if PDLIM2 were again repressed, this would facilitate MErT 
and potential tumor growth at a secondary site. A study showing 
vitamin D–mediated regulation of PDLIM2 expression in breast 
cancer further illustrates how PDLIM2 expression may determine 
phenotype (Vanoirbeek et al., 2013).
In summary, we showed that PDLIM2 is required for mainte-
nance of a gene expression program that supports the mesenchy-
mal phenotype associated with EMT. We propose that PDLIM2 is 
an essential courier protein linking cytoskeleton signaling to CSN-
mediated control of stability and activation of key transcriptional 
regulators of EMT. The function of PDLIM2 and the possibilities for 
regulating both its expression and subcellular localization reflect 
the potential for plasticity in epithelial cell differentiation in cancer 
progression.
ubiquitin ligases, and deubiquitinating proteins (Kato and Yoneda-
Kato, 2009). Several oncogenes and tumor suppressors are known 
to have modified CSN activity (β-catenin, NFκB, p53, p27, MDM2; 
FIGURE 8: PDLIM2 regulates CSN5 AND CSN activity. 
(A) Neddylated Cul1 was detected by Western blotting of cytoplasmic 
(CY) and nuclear (N) fractions from shScramble and two clones of 
shPDLIM2 DU145 cells with cullin 1 antibody. Cell fraction loading 
controls are tubulin (CY) and PARP (N). Quantification of nuclear 
neddylated Cul1 measured as percentage of total Cul1 using Odyssey 
software. (B) Western blotting of P27, CSN5, PDLIM2, and tubulin in 
DU145 shScramble and shPDLIM2 cells. Quantification of P27 
normalized to tubulin using Odyssey software is shown as mean fold 
change ±SEM from three independent experiments. (C) Neddylated 
Cul3 was detected by Western blotting of cytoplasmic (CY) and 
nuclear (N) fractions from shScramble shPDLIM2 DU145 cells. Cell 
fraction loading controls are tubulin (CY) and PARP (N). Quantification 
of total cullin 3 in cytoplasmic fractions normalized to tubulin and 
neddylated cullin 3 in nuclear fractions normalized to PARP (left 
graph). Quantification of P27 normalized to tubulin (right graph) 
using Odyssey software. (D) Whole-cell lysates were prepared from 
MCF7 cells expressing GFP-EV or GFP-PDLIM2 and probed for p27, 
PDLIM2, and actin as loading control. Quantification of P27 
normalized to tubulin using Odyssey software.
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cells were photographed with a Nikon TE300 inverted microscope 
equipped with a Nikon DXM1200F digital camera (Micron Optical, 
Wexford, Ireland). Images were captured and processed using Meta-
Morph software, version 6.2r6 (Molecular Devices, Sunnyvale, CA).
For immunofluorescence, cells were cultured on collagen-coated 
glass coverslips, washed, and then fixed using 3.75% formaldehyde. 
Cells were probed with primary antibodies, followed by Cy2- or 
Cy3-conjugated secondary antibodies, and nuclei were visualized 
with Hoechst dye as described previously (Loughran et al., 2005a). 
Cells were photographed using a Nikon Eclipse E600 microscope 
equipped with a SPOT digital camera and SPOT software, version 
4.6 (Diagnostic Instruments, Sterling Heights, MI). For analysis of 
polarization of MTOCs, confluent monolayers of cells cultured on 
collagen-coated glass coverslips were wounded, washed, reincu-
bated with medium, and allowed to migrate for 6 h. Cells were then 
fixed in ice-cold methanol/5 mM ethylene glycol tetraacetic acid 
and processed for immunofluorescence detection of γ-tubulin. All 
images were processed using Photoshop CS2, version 9.0.2 (Adobe, 
San Jose, CA).
Proliferation, colony scattering, and soft agarose assays
Cells were seeded at equal densities in RPMI/10% FBS in wells of a 
24-well plate. Cells were fixed and stained with 0.5% crystal vio-
let/20% ethanol solution every 24 h for 5 d. Stained cells were 
scanned and quantified on the Odyssey Image scanner system 
(LI-COR Biosciences).
Colony scattering assays were performed by plating cells at low 
density on collagen-coated plates. Anchorage-independent growth 
was determined by assessing colony formation in soft agarose, as 
described previously (Loughran et al., 2005a). After 4–7 wk, colonies 
were stained with crystal violet and counted.
Electric cell-substrate impedance sensing and wound-
healing assays
For ECIS migration assays (Applied BioPhysics, Troy, NY), cells were 
plated at high densities on collagen-coated eight-well ECIS array 
slides containing one electrode per well. Confluent monolayers 
were electrically wounded with 6 V for 30 s. Capacitance of the cells 
on the wound site was immediately and consistently recorded every 
30 s for a period of 15–25 h.
For analysis of cofilin phosphorylation status, multiple wounds 
were scored on confluent cell cultures with sterile pipette tips. Cul-
tures were washed, reincubated with growth medium, and allowed 
to migrate for 6 h before cell lysis and Western blotting.
NFκB-p65 activation and dual-luciferase assay
NFκB activity was measured using a dual-luciferase assay (Cignal 
NFκB reporter (luc) Kit; SABiosciences, Qiagen, Crawley, UK) as de-
scribed previously (Healy and O’Connor, 2009). Cells were trans-
fected with a NFκB dual-luciferase reporter plasmid (Super Array, 
Madison, WI) and pCMV-p65 plasmid. Cells were cultured for 48 h 
to assess basal activity, or after 36 h, cells were stimulated with 
20 ng/ml TNF-α for 4 h. Cell lysates were analyzed for luciferase 
activity of the reporter plasmid using a dual-luciferase reporter assay 
system kit (Promega, Madison, WI) and a TD20/20 luminometer 
(Promega).
Statistical analysis
Data were analyzed for statistical significance using Student’s t test 
to compare samples where appropriate. p < 0.05 was deemed sig-
nificant, and graded p values are represented as follows: *p < 0.05, 
**p < 0.005, and ***p < 0.0005.
MATERIALS AND METhODS
Cell culture and generation of shPDLIM2-expressing 
cell lines
DU145 and MDA-MB-231 cells were cultured in RPMI-1640 or 
DMEM, respectively, supplemented with 10% fetal bovine serum 
(FBS), 1 mM l-glutamine, and 5 mg/ml penicillin/streptomycin at 
37°C with 5% CO2. Cell lines stably expressing shRNA were 
generated by transfection with pSUPER vectors encoding shRNA 
targeting PDLIM2 (shPDLIM2, ACATAATCGTGGCCATCAA) or a 
control shRNA (shScramble, TGACATGATAATACTCTCT) using 
Lipofectamine (DU145; Invitrogen, Paisley, United Kingdom) or 
Lipofectamine 2000 (MDA-MB-231), following the manufacturer’s 
protocol. Cells were cultured in the presence of 1 mg/ml G418 
(Calbiochem, La Jolla, CA) for 2–4 wk, at which time individual 
clones were screened for expression of PDLIM2 by Western 
blotting.
Generation of MCF7–GFP PDLIM2 cell lines
MCF7 cells were transfected with pEGFP–empty vector or pEGFP-
PDLIM2 constructs using Lipofectamine, and stable clones were 
generated after selection in 1 mg/ml G418 as described above.
RNA isolation, cDNA synthesis, and real-time 
semiquantitative reverse transcription PCR
Total RNA was extracted from cells using the TRIzol method 
(Invitrogen) and cDNA synthesized from 2 μg using Moloney mu-
rine leukemia virus reverse transcriptase (MLTV) with an oligo-
dT12-18 primer (Invitrogen). For real-time quantitative reverse 
transcription PCR analysis, equal amounts of cDNA were amplified 
using Quantitect SYBR Green PCR Kit (Qiagen Sciences, German-
town, MD) in an ABI Prism 7900HT instrument (Applied Biosys-
tems, Foster City, CA). The Supplemental Experimental Procedures 
lists primer sequences.
Cell lysates, subcellular fractions, Western blotting, 
and immunoprecipitation
Total cellular protein extracts and cytoplasmic, soluble, and insolu-
ble nuclear extracts were prepared as described previously (Healy 
and O’Connor, 2009). The purity of the fractions was confirmed by 
Western blotting with anti-HSP90 (cytoplasm marker), anti-PARP 
(soluble nuclear fraction marker), and anti–lamin B (insoluble nuclear 
fraction marker).
For immunoprecipitations (IPs), cell lysates prepared in 50 mM 
Tris-HCl, pH 7.4, 0.2% Triton X-100, and 10% glycerol (supple-
mented with phosphatase and protease inhibitors) were incubated 
with 2–3 μg of antibody overnight, followed by incubation with pro-
tein agarose G beads for 3 h on a rotator at 4°C. Beads were washed 
three times with ice-cold lysis buffer and proteins eluted by boiling 
in SDS–PAGE loading buffer. Protein input controls are 40–50 μg of 
protein from lysates used for IPs.
All protein samples for Western blot analysis were separated by 
10% SDS–PAGE and transferred to a nitrocellulose membrane. After 
overnight incubation with primary antibody, membranes were 
probed with IRdye700 or 800–conjugated secondary antibodies, 
and proteins were detected using the Odyssey Image scanner sys-
tem (LI-COR Biosciences, Cambridge, United Kingdom). The ap-
proximate protein molecular weight in kilodaltons is indicated on 
the left of each Western blot panel.
Immunofluorescence and microscopy
For cell morphology analysis by phase microscopy, cells were cul-
tured for 48 h on 10-cm tissue culture plates. Multiple fields of live 
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Gene expression profiling and data analysis
RNA was extracted from three separate cultures of the DU145 cell 
lines (shScramble or shPDLIM2 DU145) and prepared by reverse 
transcription as probes for hybridization to HGU133 Plus 2.0 
Affymetrix gene chips at Almac Diagnostics (Craigavon, Northern 
Ireland) using three chips for each cell line. The full, normalized gene 
list (54,675 genes) was filtered based on confidence values using 
Student’s t test to generate a stringent list. Gene expression differ-
ences of ≥1.5-fold, with p ≤ 0.05, were considered significantly dif-
ferent from expression in the control samples. This list of 663 differ-
entially expressed genes was further refined to remove duplicates 
and nondescribed proteins, and the most statistically significant 
(lowest p value <0.05) of multiple transcripts was used to represent 
the target gene.
The final list consisting of 457 genes differentially expressed be-
tween the shScramble and shPDLIM2 DU145 cells was analyzed us-
ing IPA software (Ingenuity Systems, Redwood City, CA) “Core 
Analysis” to assess which signaling pathways, cellular processes, 
and transcription factors were affected by PDLIM2 suppression. For 
cellular function “Activation State” predictions, the IPA software 
considers a regulation z-score value of >2.0 for activation and <−2.0 
for inhibition of cellular functions as statistically significant. A heat 
map was generated using JColorGrid software for visualization of 
biological measurements (Joachimiak et al., 2006).
Spot synthesis of peptides and overlay analysis
Peptides arrays of CSN subunits in nitrocellulose were generated as 
previously described (Kiely et al., 2008, 2009). Essentially, scanning 
libraries of overlapping 18-mer peptides covering the entire se-
quence of CSN subunits were produced by automatic SPOT synthe-
sis and synthesized on continuous cellulose membrane supports on 
Whatman 50 cellulose using 9-fluorenylmethyloxycarbonyl chemis-
try with the MultiPep RS system (Intavis Bioanalytical Instruments, 
Cologne, Germany). The interaction of PDLIM2 with the CSN sub-
units arrays was investigated by overlaying the cellulose membranes 
with lysates of DU145 shScramble (100 μg/ml protein in NP-40 lysis 
buffer) at 37°C for 3 h. Bound PDLIM2 was detected using PDLIM2 
antibody and enhanced chemiluminescence (GE Healthcare, Amer-
sham, Little Chalfont, United Kingdom). Intensity was determined 
by densitometric analysis using ImageJ software (National Institutes 
of Health, Bethesda, MD). Substitution arrays were performed in a 
similar manner, except that alanines were substituted by glutamic 
acids and all other amino acids were substituted by alanines.
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